Trial Profile
Phase II study of nivolumab + bevacizumab + paclitaxel in patients with HER2-negative metastatic breast cancer Nivolumab Evaluation With BEvacizumab And pacliTaxel (NEWBEAT) study (WJOG9917B)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Dec 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms NEWBEAT
- 07 Dec 2022 Status changed from active, no longer recruiting to completed.
- 18 Jun 2022 Primary endpoint(Overall response rate) has been met, according to the results published in the European Journal of Cancer.
- 18 Jun 2022 Primary results(WJOG9917B) and biomarker analysis(WJOG9917BTR) published in the European Journal of Cancer.